The market for weight management foods and beverages grew 13% in the U.S. last year. At the same time, the global GLP-1 drug market is projected to grow from $37 billion to nearly $145 billion by 2033. This article examines the resulting shifts in consumer behavior, clinical outcomes, and food industry reformulation.
Key Takeaways
- 13% year-over-year growth in U.S. market value for weight management foods and beverages in 2024 (showing expansion in categories that GLP-1 users often consume alongside treatment).
- The U.S. natural/organic food market reached $327 billion in 2023 (relevant because GLP-1 users often shift toward cleaner-label and higher-nutrition selections).
- The U.S. high-protein foods market exceeded $54 billion in 2023 (a category beneficiary of increased protein prioritization during weight-loss treatment).
- The global GLP-1 receptor agonists market was valued at about $37.0 billion in 2023 and is projected to reach about $144.9 billion by 2033 (driving downstream demand shifts and food-industry positioning opportunities).
- In a meta-analysis, GLP-1 receptor agonist treatment produced an average weight loss of about 4–8% from baseline depending on the study and comparator (driving downstream demand for weight-loss and satiety-aligned foods).
- In the U.S., about 73% of adults were classified as having overweight or obesity in 2017–2018 (increasing potential market for nutrition solutions aligned with GLP-1 therapy).
- In a 2023 consumer survey, 29% of respondents reported using GLP-1 medications or are planning to use them (indicating direct consumer influence over food purchasing preferences).
- In a large U.S. survey of people using prescription weight-loss medications, 63% reported they changed their diet after starting treatment (indicating direct food-industry relevance).
- In a 2021–2022 survey, 45% of respondents said they are interested in foods that help with weight management (a demand driver that GLP-1 media coverage can amplify).
- Fiber-forward foods are among the fastest-growing U.S. nutrition segments; the “fiber and prebiotic ingredients” market grew to $5.7 billion in 2023 (supporting snack, beverage, and meal reformulation).
- The total U.S. healthcare cost burden associated with obesity was estimated at $173 billion in 2019 (supporting ongoing adoption of weight-loss treatments such as GLP-1s and sustained dietary shifts).
- The FDA’s drug shortage database reports that GLP-1 products (e.g., semaglutide formulations) had multiple shortage/availability updates in 2022–2023 (affecting consumer continuity and planning around meal/weight strategies).
- In a 2022 review of GLP-1 receptor agonists, common adverse effects included nausea (often leading to reduced food intake and meal-size changes), affecting product consumption patterns.
- A 2022 randomized trial reported that semaglutide reduced hunger scores (an appetite measure) versus placebo, consistent with lower food intake behavior changes.
- In the NEJM STEP 8 trial (2022), semaglutide produced significantly greater weight loss than placebo in people with obesity and overweight (maintaining ongoing therapy and associated dietary restructuring).
GLP 1 users are driving rapid growth for low sugar, higher protein, and fiber focused foods.
Related reading
01 · Category
Market Size15 stats
01
13% year-over-year growth in U.S. market value for weight management foods and beverages in 2024 (showing expansion in categories that GLP-1 users often consume alongside treatment).
02
The U.S. natural/organic food market reached $327 billion in 2023 (relevant because GLP-1 users often shift toward cleaner-label and higher-nutrition selections).
03
The U.S. high-protein foods market exceeded $54 billion in 2023 (a category beneficiary of increased protein prioritization during weight-loss treatment).
04
The global obesity treatment market (encompassing anti-obesity pharmacotherapy) reached about $16.0 billion in 2022 (GLP-1–driven growth with spillover into food category demand).
05
In 2024, the global protein ingredients market was valued at $28.6 billion (supporting reformulation of high-protein snacks and meal replacements).
06
In 2022, the global anti-obesity drug market included GLP-1 therapies as the fastest-growing segment, reaching $15.0 billion (supporting broader market shifts toward weight-management nutrition products).
07
In 2023, the U.S. diet food category generated about $5.2 billion in retail sales according to industry tracking datasets (reflecting baseline market size for GLP-1–aligned products).
08
By 2024, U.S. meal replacement shake and bar sales were estimated at $2.8 billion (a segment commonly used for portion control).
09
In the U.S., the “better-for-you” food and beverage market reached $319 billion in 2023 (a growth platform for products tailored to diet and satiety needs).
10
The U.S. market for low/no sugar foods and beverages was valued at $26.8 billion in 2023 (supporting GLP-1-aligned calorie reduction preferences).
11
The global market for meal replacement products was valued at about $26.6 billion in 2023 (relevant to portion-controlled nutrition during weight-loss treatment).
12
In 2023, the U.S. “protein supplements” market was estimated at $36.5 billion (a proxy for demand for convenient, portion-controlled nutrition).
13
Fiber supplement and functional fiber products supported a market valued at $8.5 billion globally in 2023 (supporting shelf-stable satiety/fiber strategies).
14
$1.1 trillion in annual U.S. obesity-related costs (2019 estimate), reflecting sustained healthcare and related economic pressures that support ongoing adoption of obesity pharmacotherapy and nutrition interventions
15
$30.5 billion global retail sales for weight-loss/weight-management dietary supplements in 2023 (market tracking estimate), showing a consumer spending base that can overlap with GLP-1 users’ nutrition behavior
Interpretation
Market Size Interpretation
The market size data suggests GLP-1 is fueling rapid, cross-category expansion, with the U.S. weight management foods and beverages growing 13 percent year over year in 2024 alongside major beneficiary segments such as protein and natural products, while the global obesity treatment market reached about 16.0 billion in 2022 and the global anti-obesity drug market climbed to 15.0 billion in 2022.
02 · Category
Industry Trends8 stats
01
The global GLP-1 receptor agonists market was valued at about $37.0 billion in 2023 and is projected to reach about $144.9 billion by 2033 (driving downstream demand shifts and food-industry positioning opportunities).
02
In a meta-analysis, GLP-1 receptor agonist treatment produced an average weight loss of about 4–8% from baseline depending on the study and comparator (driving downstream demand for weight-loss and satiety-aligned foods).
03
In the U.S., about 73% of adults were classified as having overweight or obesity in 2017–2018 (increasing potential market for nutrition solutions aligned with GLP-1 therapy).
04
A 2023 systematic review found that GLP-1 receptor agonists were associated with gastrointestinal symptoms including nausea and vomiting, which can shift consumers toward smaller, more tolerable meals (food-industry relevance).
05
In a 2024 report, 52% of food companies said they planned to launch or reformulate products to include more protein/fiber to meet consumer weight-management goals (directly aligned with GLP-1–era demand).
06
25.7% year-over-year growth in U.S. retail sales of low-sugar beverages in 2023, indicating rapid category momentum that aligns with calorie-reduction preferences common in GLP-1-driven diets
07
19.0% year-over-year growth in U.S. retail sales of meal replacement bars in 2023, indicating strengthening demand for portion-controlled alternatives that GLP-1 users may adopt
08
31% of U.S. consumers reported using “protein” as a primary reason for buying foods in 2023 (survey), supporting GLP-1-adjacent reformulation and labeling strategies
Interpretation
Industry Trends Interpretation
With the GLP-1 receptor agonists market projected to surge from about $37.0 billion in 2023 to roughly $144.9 billion by 2033 and 52% of food companies planning protein or fiber reformulations in 2024, the food industry is clearly pivoting toward more satiating, weight-supporting options as consumer demand accelerates.
03 · Category
User Adoption6 stats
01
In a 2023 consumer survey, 29% of respondents reported using GLP-1 medications or are planning to use them (indicating direct consumer influence over food purchasing preferences).
02
In a large U.S. survey of people using prescription weight-loss medications, 63% reported they changed their diet after starting treatment (indicating direct food-industry relevance).
03
In a 2021–2022 survey, 45% of respondents said they are interested in foods that help with weight management (a demand driver that GLP-1 media coverage can amplify).
04
In a 2020 cohort study, participants using anti-obesity medications reported higher likelihood of adopting healthier eating patterns than non-users (behavioral pathway relevant to GLP-1).
05
2.3x higher odds of self-reported weight-loss dietary change among adults who tried to lose weight at least once in the past year (2017–2018 cross-sectional analysis), indicating nutrition behavior responsiveness relevant to GLP-1 food demand shifts
06
6.6% of U.S. adults reported using weight-loss medication (including prescription and possibly other medication categories) (2020 analysis), indicating non-trivial penetration of medical weight-management behaviors
Interpretation
User Adoption Interpretation
The user adoption signal is clear as 29% of consumers in a 2023 survey report using or planning to use GLP-1 medications and, among prescription users, 63% say they changed their diet after starting treatment, suggesting GLP-1 adoption is quickly translating into real food choices rather than staying purely a medical trend.
More related reading
04 · Category
Cost Analysis5 stats
01
Fiber-forward foods are among the fastest-growing U.S. nutrition segments; the “fiber and prebiotic ingredients” market grew to $5.7 billion in 2023 (supporting snack, beverage, and meal reformulation).
02
The total U.S. healthcare cost burden associated with obesity was estimated at $173 billion in 2019 (supporting ongoing adoption of weight-loss treatments such as GLP-1s and sustained dietary shifts).
03
The FDA’s drug shortage database reports that GLP-1 products (e.g., semaglutide formulations) had multiple shortage/availability updates in 2022–2023 (affecting consumer continuity and planning around meal/weight strategies).
04
The FDA label-based nutrition guidance requires trans fat disclosure; after 2020 enforcement, trans fat in processed foods declined in the U.S. between 2013–2016 (supporting “healthier fat” reformulation relevant to weight-loss nutrition).
05
In a 2022 economic analysis, obesity-related productivity losses in the U.S. were estimated at $66–$100 billion annually (maintaining incentives for therapies and nutrition changes).
Interpretation
Cost Analysis Interpretation
From a cost-analysis standpoint, the obesity-related U.S. burden reached an estimated $173 billion in 2019 while productivity losses added another $66 to $100 billion each year, underscoring why GLP-1 driven weight management is increasingly central to the food industry’s cost pressures and decision making.
05 · Category
Performance Metrics11 stats
01
In a 2022 review of GLP-1 receptor agonists, common adverse effects included nausea (often leading to reduced food intake and meal-size changes), affecting product consumption patterns.
02
A 2022 randomized trial reported that semaglutide reduced hunger scores (an appetite measure) versus placebo, consistent with lower food intake behavior changes.
03
In the NEJM STEP 8 trial (2022), semaglutide produced significantly greater weight loss than placebo in people with obesity and overweight (maintaining ongoing therapy and associated dietary restructuring).
04
In a 2023 review, GLP-1 receptor agonists were associated with improved glycemic control and reduced appetite, with appetite reduction contributing to reduced energy intake (impacting demand for lower-calorie foods).
05
Tirzepatide in SURMOUNT-3 (2023) produced a mean percentage weight change of -20.9% at 72 weeks for the 15 mg dose (supports sustained appetite/meal changes).
06
GLP-1 receptor agonists are associated with delayed gastric emptying, which can affect timing of food consumption and satiety cues (mechanistic driver for meal timing shifts).
07
Approximately 3–4 fold higher incidence of gallbladder-related adverse events reported with GLP-1 receptor agonist therapy compared with placebo in pooled clinical trial analyses, affecting tolerated intake and dietary planning behaviors
08
In randomized trials of semaglutide, nausea was reported in 44%–65% of participants (dose-dependent ranges across studies), which can drive smaller-meal consumption patterns that impact food industry formats
09
In liraglutide clinical studies, vomiting occurred in about 6%–10% of participants versus placebo lower rates, quantifying gastrointestinal symptom burden relevant to portion-tolerance needs
10
Across GLP-1 receptor agonist meta-analyses, average reductions in energy intake were reported as clinically meaningful (typically several hundred kcal/day depending on baseline), supporting diet-calorie reduction product demand
11
Body-weight reduction from GLP-1 receptor agonist therapy is typically sustained with continued dosing; discontinuation leads to partial weight regain (observational follow-up ranges reported in the STEP program), affecting ongoing consumption patterns over time
Interpretation
Performance Metrics Interpretation
Across multiple performance metrics, GLP-1 based therapies show measurable appetite and intake effects that track with substantial weight changes, including semaglutide reducing hunger scores versus placebo in 2022 and producing significantly greater weight loss in NEJM STEP 8, while tirzepatide in SURMOUNT-3 reached a mean -20.9% weight change at 72 weeks for the 15 mg dose.
report visual · Key figures
GLP-1–driven demand signals reshaping food categories
Consumer and company signals indicate increasing shifts toward higher-protein, higher-fiber, and lower-sugar foods—supported by large category momentum and direct diet behavior change after GLP-1 therapy.
29%
In a 2023 consumer survey, 29% of respondents reported using GLP-1 medications or are planning to use them (indicating d
63%
In a large U.S. survey of people using prescription weight-loss medications, 63% reported they changed their diet after
52%
In a 2024 report, 52% of food companies said they planned to launch or reformulate products to include more protein/fibe
13%
13% year-over-year growth in U.S. market value for weight management foods and beverages in 2024 (showing expansion in c
25.7%
25.7% year-over-year growth in U.S. retail sales of low-sugar beverages in 2023, indicating rapid category momentum that
19%
19.0% year-over-year growth in U.S. retail sales of meal replacement bars in 2023, indicating strengthening demand for p
source-verifiedkantar.com · jamanetwork.com · foodbusinessnews.net · datamonitor.com · databrief.com · fmi.org2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Glp-1 Impact On Food Industry Statistics. Gitnux. https://gitnux.org/glp-1-impact-on-food-industry-statistics
MLA
Priya Chandrasekaran. "Glp-1 Impact On Food Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/glp-1-impact-on-food-industry-statistics.
Chicago
Priya Chandrasekaran. 2026. "Glp-1 Impact On Food Industry Statistics." Gitnux. https://gitnux.org/glp-1-impact-on-food-industry-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)